# Olivia Newton-John Cancer Research Institute: Early phase 1 study in IDH Wildtype Glioblastoma, Glioblastoma (GBM) (12 participants)

**Score:** 55/100

| Field | Value |
|---|---|
| Sponsor | Olivia Newton-John Cancer Research Institute |
| Sponsor type | Academic and hospital |
| Study | Biomarker-guided RAdiation-deferring Treatment in Younger GBM Patients - Pilot Study |
| NCT ID | NCT07908147 |
| Phase | Early phase 1 |
| Status | not yet recruiting |
| Conditions | IDH Wildtype Glioblastoma; Glioblastoma (GBM) |
| Intervention types | drug |
| Target enrollment | 12 |
| Site countries | Australia |
| Posted | 2026-10-30 |
| Planned start | 2027-03 |
| Event | Newly registered study |
| Event date | 2026-10-30 |

## Why this score
- Posted in the last two weeks.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07908147). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.